$IRON News

Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92

Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115

Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124

Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110

Disc Medicine: APOLLO Changes The Story, But How Much Upside Remains

Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling Plan

Disc Medicine (IRON) APOLLO Win Puts Its Valuation Discount Back In Focus

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

What Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?

Disc’s once-spurned rare disease drug to get a second chance at approval

Disc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission

Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript

Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes

Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints

BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

Disc Medicine Soars 35% as Rare Disease Drug Hits Every Phase 3 Endpoint: “A Potential Breakthrough”

Disc Medicine Shares Rise 60% After Phase 3 Bitopertin Trial Meets Primary and Secondary Endpoints

Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study